Dr. Patrick Cobb, MD
Claim this profileSt. Vincent Frontier Cancer Center
Area of expertise
Breast Cancer
Patrick Cobb, MD has run 4 trials for Breast Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Patrick Cobb, MD has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
St Vincent Frontier Cancer Center
Saint Vincent Frontier Cancer Center
Clinical Trials Patrick Cobb, MD is currently running
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting
1 award
Phase 2 & 3
20 criteria
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting
2 awards
Phase 3
More about Patrick Cobb, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Patrick Cobb, MD has experience with
- Carboplatin
- Pembrolizumab
- Placebo
- Pemetrexed
- Rituximab
- Atezolizumab
Breakdown of trials Patrick Cobb, MD has run
Breast Cancer
Non-Small Cell Lung Cancer
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Patrick Cobb, MD specialize in?
Patrick Cobb, MD focuses on Breast Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Patrick Cobb, MD currently recruiting for clinical trials?
Yes, Patrick Cobb, MD is currently recruiting for 4 clinical trials in Billings Montana. If you're interested in participating, you should apply.
Are there any treatments that Patrick Cobb, MD has studied deeply?
Yes, Patrick Cobb, MD has studied treatments such as Carboplatin, Pembrolizumab, Placebo.
What is the best way to schedule an appointment with Patrick Cobb, MD?
Apply for one of the trials that Patrick Cobb, MD is conducting.
What is the office address of Patrick Cobb, MD?
The office of Patrick Cobb, MD is located at: St. Vincent Frontier Cancer Center, Billings, Montana 59102-6746 United States. This is the address for their practice at the St. Vincent Frontier Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.